LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Incyte Corp

Suletud

SektorTervishoid

67.7 -1.74

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

67.47

Max

69

Põhinäitajad

By Trading Economics

Sissetulek

-43M

158M

Müük

-126M

1.1B

P/E

Sektori keskmine

349.45

51.748

Aktsiakasum

1.16

Kasumimarginaal

15.025

Töötajad

2,617

EBITDA

-80M

257M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+4.54% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-2.5B

14B

Eelmine avamishind

69.44

Eelmine sulgemishind

67.7

Uudiste sentiment

By Acuity

27%

73%

76 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Incyte Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. juuni 2025, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Millicom to Acquire Telefonica Ecuador for $380 Million

13. juuni 2025, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13. juuni 2025, 23:20 UTC

Omandamised, ülevõtmised, äriostud

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13. juuni 2025, 23:09 UTC

Omandamised, ülevõtmised, äriostud

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13. juuni 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13. juuni 2025, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Millicom to Acquire Telefonica Ecuador for $380M

13. juuni 2025, 22:04 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Better Data Facilitate Investments In Oil Patch -- Market Talk

13. juuni 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13. juuni 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Bunge: Outside Date Extended to July 3

13. juuni 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13. juuni 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Bunge Gets Mexico Approval for Viterra Deal

13. juuni 2025, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Bunge Gets China Approval for Viterra Deal

13. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. juuni 2025, 20:45 UTC

Omandamised, ülevõtmised, äriostud

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13. juuni 2025, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Anne Wojcicki Wins Bidding for 23andMe -- Update

13. juuni 2025, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13. juuni 2025, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13. juuni 2025, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13. juuni 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13. juuni 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13. juuni 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13. juuni 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13. juuni 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13. juuni 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13. juuni 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13. juuni 2025, 17:02 UTC

Omandamised, ülevõtmised, äriostud

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13. juuni 2025, 17:02 UTC

Omandamised, ülevõtmised, äriostud

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13. juuni 2025, 17:02 UTC

Omandamised, ülevõtmised, äriostud

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13. juuni 2025, 17:02 UTC

Omandamised, ülevõtmised, äriostud

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Incyte Corp Prognoos

Hinnasiht

By TipRanks

4.54% tõus

12 kuu keskmine prognoos

Keskmine 72.36 USD  4.54%

Kõrge 89 USD

Madal 52 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Incyte Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

6

Osta

12

Hoia

1

Müü

Tehniline skoor

By Trading Central

59.52 / 62.66Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

76 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation